Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics

Huntington’s disease (HD) is a progressive neurodegenerative disease characterized by preferential loss of neurons in the striatum in patients, which leads to motor and cognitive impairments and death that often occurs 10-15 years after the onset of symptoms. The expansion of a glutamine repeat (>36 glutamines) in the N-terminal region of huntingtin (HTT) has been defined as the cause of HD, but the mechanism underlying neuronal death remains unclear. Multiple mechanisms, including inflammation, may jointly contribute to HD pathogenesis. Altered inflammation response is evident even before the onset of classical symptoms of HD. In this review, we summarize the current evidence on immune and inflammatory changes, from HD animal models to clinical phenomenon of patients with HD. The understanding of the impact of inflammation on HD would help develop novel strategies to treat HD.

[1]  Lidia Gaffke,et al.  Behavioral- and blood-based biomarkers for Huntington's disease: Studies on the R6/1 mouse model with prospects for early diagnosis and monitoring of the disease , 2022, Brain, behavior, & immunity - health.

[2]  T. Sumathi,et al.  5,6,7 trihydroxy flavone armoured neurodegeneration caused by Quinolinic acid induced huntington’s like disease in rat striatum - reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathological aspects , 2021, Neuroscience Research.

[3]  A. Minassi,et al.  Betulinic Acid Hydroxamate is Neuroprotective and Induces Protein Phosphatase 2A-Dependent HIF-1α Stabilization and Post-transcriptional Dephosphorylation of Prolyl Hydrolase 2 , 2021, Neurotherapeutics.

[4]  Shihua Li,et al.  Lack of association of somatic CAG repeat expansion with striatal neurodegeneration in HD knock-in animal models. , 2021, Human molecular genetics.

[5]  R. Magin,et al.  Evaluation of early microstructural changes in the R6/1 mouse model of Huntington's disease by ultra-high field diffusion MR imaging , 2021, Neurobiology of Aging.

[6]  Weihong Gu,et al.  Altered Gut Microbiota Related to Inflammatory Responses in Patients With Huntington’s Disease , 2021, Frontiers in Immunology.

[7]  B. Hutter-Paier,et al.  Quantification of Huntington’s Disease Related Markers in the R6/2 Mouse Model , 2021, Frontiers in Molecular Neuroscience.

[8]  G. Sancesario,et al.  Pyroptotic cell death in the R6/2 mouse model of Huntington’s disease: new insight on the inflammasome , 2020, Cell Death Discovery.

[9]  J. Alberch,et al.  Reduced Fractalkine Levels Lead to Striatal Synaptic Plasticity Deficits in Huntington’s Disease , 2020, Frontiers in Cellular Neuroscience.

[10]  M. Heiman,et al.  Interleukin-6 deficiency exacerbates Huntington’s disease model phenotypes , 2020, Molecular Neurodegeneration.

[11]  Shihua Li,et al.  Phosphorylation of myelin regulatory factor by PRKG2 mediates demyelination in Huntington's disease , 2020, EMBO reports.

[12]  T. Yamashita,et al.  Immunotherapies in Huntington's disease and α-Synucleinopathies , 2020, Frontiers in Immunology.

[13]  F. Sellebjerg,et al.  Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease , 2019, Annals of neurology.

[14]  R. Faull,et al.  The Role of Microglia and Astrocytes in Huntington’s Disease , 2019, Front. Mol. Neurosci..

[15]  M. Zurovec,et al.  Expression of Human Mutant Huntingtin Protein in Drosophila Hemocytes Impairs Immune Responses , 2019, Front. Immunol..

[16]  C. Guatimosim,et al.  Inflammatory changes in peripheral organs in the BACHD murine model of Huntington's disease. , 2019, Life sciences.

[17]  J. Schneider,et al.  GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease , 2019, Scientific Reports.

[18]  S. Tabrizi,et al.  Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment , 2019, Scientific Reports.

[19]  M. Greenberg,et al.  Sensory lesioning induces microglial synapse elimination via ADAM10 and fractalkine signaling , 2019, Nature Neuroscience.

[20]  Radha,et al.  GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease , 2019, Scientific Reports.

[21]  R. Gold,et al.  Author Correction: Laquinimod treatment in the R6/2 mouse model , 2019, Scientific Reports.

[22]  M. Hayden,et al.  Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease , 2018, Molecular Neurobiology.

[23]  N. Lago,et al.  CD200 modulates spinal cord injury neuroinflammation and outcome through CD200R1 , 2018, Brain, Behavior, and Immunity.

[24]  T. Dawson,et al.  Animal models of neurodegenerative diseases , 2018, Nature Neuroscience.

[25]  S. Tabrizi,et al.  In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington’s disease , 2018, Scientific Reports.

[26]  R. Gold,et al.  Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model , 2018, Journal of Neuroinflammation.

[27]  Shihua Li,et al.  A Huntingtin Knockin Pig Model Recapitulates Features of Selective Neurodegeneration in Huntington’s Disease , 2018, Cell.

[28]  L. Raymond,et al.  HttQ111/+ Huntington’s Disease Knock-in Mice Exhibit Brain Region-Specific Morphological Changes and Synaptic Dysfunction , 2018, Journal of Huntington's disease.

[29]  R. Ransohoff,et al.  Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model , 2018, Journal of Neuroinflammation.

[30]  D. Centonze,et al.  Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake , 2018, Journal of Neuroinflammation.

[31]  A. Huber,et al.  An emerging role for eotaxins in neurodegenerative disease. , 2016, Clinical immunology.

[32]  K. Fouad,et al.  Disease‐modifying effects of ganglioside GM1 in Huntington's disease models , 2017, EMBO molecular medicine.

[33]  K. Yamanaka.  [Roles of Microglia in Neurodegenerative Diseases]. , 2017, Brain and nerve = Shinkei kenkyu no shinpo.

[34]  R. Gold,et al.  Laquinimod treatment in the R6/2 mouse model , 2017, Scientific Reports.

[35]  S. Vermeire,et al.  Novel Targeted Therapies for Inflammatory Bowel Disease. , 2017, Trends in pharmacological sciences.

[36]  B. Leavitt,et al.  Potential biomarkers to follow the progression and treatment response of Huntington’s disease , 2016, The Journal of experimental medicine.

[37]  J. Raper,et al.  Increased irritability, anxiety, and immune reactivity in transgenic Huntington’s disease monkeys , 2016, Brain, Behavior, and Immunity.

[38]  Ignacio S. Caballero,et al.  Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor , 2016, Proceedings of the National Academy of Sciences.

[39]  D. Ehrnhoefer,et al.  Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons , 2016, Experimental Neurology.

[40]  M. Hayden,et al.  Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease , 2016, Scientific Reports.

[41]  J. Motlík,et al.  Revelation of the IFNα, IL-10, IL-8 and IL-1β as promising biomarkers reflecting immuno-pathological mechanisms in porcine Huntington's disease model , 2016, Journal of Neuroimmunology.

[42]  D. Bonchev,et al.  Network analysis of human post-mortem microarrays reveals novel genes, microRNAs, and mechanistic scenarios of potential importance in fighting huntington's disease , 2016, Computational and structural biotechnology journal.

[43]  J. Bachevalier,et al.  Progressive Cognitive Deficit, Motor Impairment and Striatal Pathology in a Transgenic Huntington Disease Monkey Model from Infancy to Adulthood , 2015, PloS one.

[44]  F. Giorgini,et al.  The kynurenine pathway and neurodegenerative disease. , 2015, Seminars in cell & developmental biology.

[45]  M. Hayden,et al.  Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease , 2015, Neurobiology of Disease.

[46]  Yih-Ru Wu,et al.  Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model , 2015, Brain, Behavior, and Immunity.

[47]  S. Tabrizi,et al.  Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models , 2014, Neurobiology of Disease.

[48]  M. Varrin-doyer,et al.  Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis , 2014, Experimental Neurology.

[49]  Yih-Ru Wu,et al.  Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. , 2014, Human molecular genetics.

[50]  F. Gage,et al.  Mutant Huntingtin Promotes Autonomous Microglia Activation via Myeloid Lineage-determining Factors Fold Difference from the Mean , 2022 .

[51]  K. J. Murphy,et al.  Neuron–glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage , 2013, Open Biology.

[52]  J. Purcell,et al.  Morphometric analysis of Huntington's disease neurodegeneration in Drosophila. , 2013, Methods in molecular biology.

[53]  A. Basu,et al.  A friend in need may not be a friend indeed: role of microglia in neurodegenerative diseases. , 2013, CNS & neurological disorders drug targets.

[54]  R. Linker,et al.  The Role of the Immune System in Huntington's Disease , 2013, Clinical & developmental immunology.

[55]  F. Borrego.  The CD300 molecules: an emerging family of regulators of the immune system. , 2013, Blood.

[56]  D. Mochly‐Rosen,et al.  A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity , 2013, Journal of Cell Science.

[57]  N. Osada,et al.  Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history , 2012, Genes to cells : devoted to molecular & cellular mechanisms.

[58]  M. DiFiglia,et al.  A transgenic minipig model of Huntington's Disease. , 2013, Journal of Huntington's disease.

[59]  Mei Kwan,et al.  Comprehensive Behavioral and Molecular Characterization of a New Knock-In Mouse Model of Huntington’s Disease: zQ175 , 2012, PloS one.

[60]  S. Tabrizi,et al.  Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease , 2012, The Journal of Neuroscience.

[61]  R. Saada,et al.  Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis , 2012, Journal of Neuroimmunology.

[62]  Blair R. Leavitt,et al.  Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease , 2012, Neurobiology of Disease.

[63]  E. Masliah,et al.  Bone Marrow Transplantation Confers Modest Benefits in Mouse Models of Huntington's Disease , 2012, The Journal of Neuroscience.

[64]  S. Tabrizi,et al.  Abnormal peripheral chemokine profile in Huntington’s disease , 2011, PLoS currents.

[65]  David Housman,et al.  Huntington's Disease: Can Mice Lead the Way to Treatment? , 2011, Neuron.

[66]  L. Menalled,et al.  Knock-in mouse models of Huntington’s disease , 2005, NeuroRX.

[67]  M. MacDonald,et al.  An ovine transgenic Huntington's disease model. , 2010, Human molecular genetics.

[68]  Chuan-en Wang,et al.  Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice* , 2010, The Journal of Biological Chemistry.

[69]  H. Lassmann,et al.  MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. , 2009, Brain : a journal of neurology.

[70]  Í. Azcoitia,et al.  Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. , 2009, Brain : a journal of neurology.

[71]  T. Möller,et al.  Distinct neuroinflammatory profile in post-mortem human Huntington's disease , 2009, Neuroreport.

[72]  P. Brundin,et al.  Beyond the brain: widespread pathology in Huntington's disease , 2009, The Lancet Neurology.

[73]  Damon H. May,et al.  Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease , 2009, Molecular & Cellular Proteomics.

[74]  N. Nukina,et al.  Induction of chemokines, MCP‐1, and KC in the mutant huntingtin expressing neuronal cells because of proteasomal dysfunction , 2009, Journal of neurochemistry.

[75]  M. Chesselet,et al.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice , 2008, Neuroscience.

[76]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[77]  J. Bachevalier,et al.  Towards a transgenic model of Huntington’s disease in a non-human primate , 2008, Nature.

[78]  Carlos Cepeda,et al.  Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.

[79]  A. Reiner,et al.  R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice , 2007, The Journal of comparative neurology.

[80]  Danielle A. Simmons,et al.  Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease , 2007, Glia.

[81]  S. Tabrizi,et al.  Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. , 2007, Journal of proteome research.

[82]  J. Ryu,et al.  Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington’s disease , 2006, Neuroscience.

[83]  M. MacDonald,et al.  Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice , 2006, Neurobiology of Disease.

[84]  K. Kaibuchi,et al.  Sema4D/plexin‐B1 activates GSK‐3β through R‐Ras GAP activity, inducing growth cone collapse , 2006, EMBO reports.

[85]  D J Brooks,et al.  Microglial activation correlates with severity in Huntington disease , 2006, Neurology.

[86]  R. Ferrante,et al.  Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. , 2006, Biochimica et biophysica acta.

[87]  Ji-Yeon Shin,et al.  Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.

[88]  M. Hayden,et al.  Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.

[89]  Steven M Hersch,et al.  Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice , 2005, The Journal of comparative neurology.

[90]  T. Stone,et al.  Tryptophan metabolism and oxidative stress in patients with Huntington's disease , 2005, Journal of neurochemistry.

[91]  S. Augood,et al.  Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease , 2004, Neurobiology of Disease.

[92]  Minocycline safety and tolerability in Huntington disease , 2004, Neurology.

[93]  T. Town,et al.  Neuronal expression of CD22: Novel mechanism for inhibiting microglial proinflammatory cytokine production , 2004, Glia.

[94]  Xiao-Jiang Li,et al.  Huntingtin-protein interactions and the pathogenesis of Huntington's disease. , 2004, Trends in genetics : TIG.

[95]  M. Chesselet,et al.  Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.

[96]  R. Ferrante,et al.  Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[97]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[98]  He Li,et al.  Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease , 2003, The Journal of Neuroscience.

[99]  J. Schiefer,et al.  Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus , 2001, Behavioural Brain Research.

[100]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[101]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[102]  P G Bhide,et al.  Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain , 2001, Journal of neuropathology and experimental neurology.

[103]  R. Albin,et al.  Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.

[104]  B. Blom,et al.  Down-regulation of the macrophage lineage through interaction with OX2 (CD200). , 2000, Science.

[105]  T. Siddique,et al.  Transgenic mouse models and human neurodegenerative disorders. , 2000, Archives of neurology.

[106]  S. W. Davies,et al.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[107]  S B Dunnett,et al.  Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.

[108]  R. Schwarcz,et al.  Early kynurenergic impairment in Huntington's Disease and in a transgenic animal model , 2000, Neuroscience Letters.

[109]  M. MacDonald,et al.  Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. , 2000, Human molecular genetics.

[110]  H. Zoghbi,et al.  Glutamine repeats and neurodegeneration. , 2000, Annual review of neuroscience.

[111]  P. Gasque,et al.  Increased Complement Biosynthesis By Microglia and Complement Activation on Neurons in Huntington's Disease , 1999, Experimental Neurology.

[112]  Stephen B. Dunnett,et al.  Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation , 1999, The Journal of Neuroscience.

[113]  W. Streit,et al.  Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[114]  J. Schneider.  GM1 Ganglioside in the Treatment of Parkinson's Disease a , 1998 .

[115]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[116]  C. Ross,et al.  Neurobiology of Huntington's Disease , 1996, Neurobiology of Disease.

[117]  S. Folstein,et al.  Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.

[118]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[119]  K. Blennow,et al.  Differences in cerebrospinal fluid gangliosides between “probable Alzheimer’s disease” and normal aging , 1992, Aging.

[120]  S. Snider,et al.  Controlled clinical trial of cannabidiol in Huntington's disease , 1991, Pharmacology Biochemistry and Behavior.